Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4

Eduardo Pauls; Ester Ballana; Gemma Moncunill; Margarida Bof́ill; Bonaventura Clotet; Cristina Ramo-Tello; José A. Esté

doi:10.1097/QAD.0b013e328320a7f8

Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4

Eduardo Pauls, Ester Ballana, Gemma Moncunill, Margarida Bof́ill, Bonaventura Clotet, Cristina Ramo-Tello, José A. Esté

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

13 Citations (Scopus)

Abstract

The alpha4beta7 integrin has been shown to serve as a coreceptor for HIV. One anti-alpha4 integrin agent (natalizumab) has been approved for the treatment of multiple sclerosis and Crohn's disease. We found that activation of CD4 + T cells with retinoic acid induced the upregulation of alpha4 and beta7 integrins. However, natalizumab failed to block the replication of HIV-1 strains in lymphoid MT-4 cells or CD4 + T cells at concentrations up to 125 μg/ml. Our results suggest that alpha4 integrins are not essential cofactors for HIV replication.

Original language	English
Pages (from-to)	266-268
Journal	AIDS
Volume	23
Issue number	2
DOIs	https://doi.org/10.1097/QAD.0b013e328320a7f8
Publication status	Published - 14 Jan 2009

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.1097/QAD.0b013e328320a7f8

Fingerprint Dive into the research topics of 'Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4'. Together they form a unique fingerprint.

Cite this

@article{82da808f727b454db6190d86d619e436,

title = "Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4",

abstract = "The alpha4beta7 integrin has been shown to serve as a coreceptor for HIV. One anti-alpha4 integrin agent (natalizumab) has been approved for the treatment of multiple sclerosis and Crohn's disease. We found that activation of CD4 + T cells with retinoic acid induced the upregulation of alpha4 and beta7 integrins. However, natalizumab failed to block the replication of HIV-1 strains in lymphoid MT-4 cells or CD4 + T cells at concentrations up to 125 μg/ml. Our results suggest that alpha4 integrins are not essential cofactors for HIV replication.",

author = "Eduardo Pauls and Ester Ballana and Gemma Moncunill and Margarida Bo{\'f}ill and Bonaventura Clotet and Cristina Ramo-Tello and Est{\'e}, {Jos{\'e} A.}",

year = "2009",

month = jan,

day = "14",

doi = "10.1097/QAD.0b013e328320a7f8",

language = "English",

volume = "23",

pages = "266--268",

number = "2",

}

TY - JOUR

T1 - Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4

AU - Pauls, Eduardo

AU - Ballana, Ester

AU - Moncunill, Gemma

AU - Bof́ill, Margarida

AU - Clotet, Bonaventura

AU - Ramo-Tello, Cristina

AU - Esté, José A.

PY - 2009/1/14

Y1 - 2009/1/14

N2 - The alpha4beta7 integrin has been shown to serve as a coreceptor for HIV. One anti-alpha4 integrin agent (natalizumab) has been approved for the treatment of multiple sclerosis and Crohn's disease. We found that activation of CD4 + T cells with retinoic acid induced the upregulation of alpha4 and beta7 integrins. However, natalizumab failed to block the replication of HIV-1 strains in lymphoid MT-4 cells or CD4 + T cells at concentrations up to 125 μg/ml. Our results suggest that alpha4 integrins are not essential cofactors for HIV replication.

AB - The alpha4beta7 integrin has been shown to serve as a coreceptor for HIV. One anti-alpha4 integrin agent (natalizumab) has been approved for the treatment of multiple sclerosis and Crohn's disease. We found that activation of CD4 + T cells with retinoic acid induced the upregulation of alpha4 and beta7 integrins. However, natalizumab failed to block the replication of HIV-1 strains in lymphoid MT-4 cells or CD4 + T cells at concentrations up to 125 μg/ml. Our results suggest that alpha4 integrins are not essential cofactors for HIV replication.

U2 - 10.1097/QAD.0b013e328320a7f8

DO - 10.1097/QAD.0b013e328320a7f8

M3 - Article

VL - 23

SP - 266

EP - 268

IS - 2

ER -